I-CLIP: Improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score

Oncology

Volumn 80, Issue 5-6, 2011, Pages 373-381

  Kaseb, Ahmed O ^a   Abbruzzese, James L ^a   Vauthey, Jean Nicolas ^a   Aloia, Thomas A ^a   Abdalla, Eddie K ^a   Hassan, Manal M ^a   Lin, E ^a   Xiao, Lianchun ^a   El Deeb, Adel S ^a   Rashid, Asif ^a   Morris, Jeffrey S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer of the Liver Italian Program (CLIP) score; Chronic liver disease; Hepatocellular carcinoma; IGF 1

Indexed keywords

BIOLOGICAL MARKER; SOMATOMEDIN C;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER OF THE LIVER ITALIAN PROGRAM SCORE; CANCER SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM;

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 79961116391     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000329040     Document Type: Article

References (31)

1. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28: 751-755.
2. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
3. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236. (Pubitemid 43112690)
4. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430. (Pubitemid 32844200)
5. Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, Lozano R, Rashid A, Abbruzzese JL, Morris JS: V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer 2011;117:2478-2485.
6. Mirici-Cappa F, Gramenzi A, Santi V, Zambruni A, Di Micoli A, Frigerio M, Maraldi F, Di Nolfo MA, Del Poggio P, Benvegnu L, Rapaccini G, Farinati F, Zoli M, Borzio F, Giannini EG, Caturelli E, Bernardi M, Trevisani F: Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: A 20-year multicentre experience. Gut 2010; 59: 387-396.
7. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 2000; 31: 840-845.
8. Farinati F, Rinaldi M, Gianni S, Naccarato R: How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000; 89: 2266-2273.
9. Levy I, Sherman M: Staging of hepatocellular carcinoma: Assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002; 50: 881-885.
10. Ueno S, Tanabe G, Sako K, Hiwaki T, Hokotate H, Fukukura Y, Baba Y, Imamura Y, Aikou T: Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 2001; 34: 529-534. (Pubitemid 32786644)
11. Llovet JM, Bruix J: Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000; 32: 679-680.
12. Chan SL, Mo FK, Johnson PJ, Liem GS, Chan TC, Poon MC, Ma BB, Leung TW, Lai PB, Chan AT, Mok TS, Yeo W: Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J Gastroenterol Hepatol 2011; 26: 340-347.
13. Tsai AL, Burke CT, Kennedy AS, Moore DT, Mauro MA, Dixon RD, Stavas JM, Bernard SA, Khandani AH, O'Neil BH: Use of yttrium- 90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010; 21: 1377-1384.
14. Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, Chen PJ, Lin ZZ, Chao TY, Cheng AL: Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 2010; 102: 981-986.
15. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS: Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drugeluting beads: A preliminary study. HPB (Oxford) 2010; 12: 174-180.
16. Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Lee PC, Loong CC, Chiang JH, Huo TI, Lee SD: Selecting an optimal staging system for hepatocellular carcinoma: Comparison of 5 currently used prognostic models. Cancer 2010; 116: 3006-3014.
17. Huitzil-Melendez FD, Capanu M, O'Reilly EM, Duffy A, Gansukh B, Saltz LL, Abou- Alfa GK: Advanced hepatocellular carcinoma: Which staging systems best predict prognosis? J Clin Oncol 2010; 28: 2889-2895.
18. Daughaday WH: The possible autocrine/ paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology 1990; 127: 1-4. (Pubitemid 20228092)
19. Buzzelli G, Dattolo P, Pinzani M, Brocchi A, Romano S, Gentilini P: Circulating growth hormone and insulin-like growth factor-I in nonalcoholic liver cirrhosis with or without superimposed hepatocarcinoma: Evidence of an altered circadian rhythm. Am J Gastroenterol 1993; 88: 1744-1748. (Pubitemid 23298126)
20. Luo SM, Tan WM, Deng WX, Zhuang SM, Luo JW: Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent nontumor tissues of hepatocellular carcinoma patients with cirrhosis. World J Gastroenterol 2005; 11: 4272-4276.
21. Su TS, Liu WY, Han SH, Jansen M, Yang-Fen TL, P'Eng FK, Chou CK: Transcripts of the insulin-like growth factors I and II in human hepatoma. Cancer Res 1989; 49: 1773-1777. (Pubitemid 19108403)
22. Stuver SO, Kuper H, Tzonou A, Lagiou P, Spanos E, Hsieh CC, Mantzoros C, Trichopoulos D: Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men. Int J Cancer 2000; 87: 118-121. (Pubitemid 30368424)
23. Su WW, Lee KT, Yeh YT, Soon MS, Wang CL, Yu ML, Wang SN: Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: One cross-sectional correlation study. J Clin Lab Anal 2010; 24: 195-200.
24. Elsammak MY, Amin GM, Khalil GM, Ragab WS, Abaza MM: Possible contribution of serum activin A and IGF-1 in the development of hepatocellular carcinoma in Egyptian patients suffering from combined hepatitis C virus infection and hepatic schistosomiasis. Clin Biochem 2006; 39: 623-629.
25. Garcia-Galiano D, Sanchez-Garrido MA, Espejo I, Montero JL, Costan G, Marchal T, Membrives A, Gallardo-Valverde JM, Munoz- Castaneda JR, Arevalo E, De la Mata M, Muntane J: Il-6 and IGF-1 are independent prognostic factors of liver steatosis and nonalcoholic steatohepatitis in morbidly obese patients. Obes Surg 2007; 17: 493-503. (Pubitemid 46850189)
26. Harrell FE CR, Pryor DB, Lee KL, Rosati RA: Evaluating the yield of medical tests. JAMA 1982; 247: 2543-2546. (Pubitemid 12155954)
27. Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA: Vascular endothelial growth factor in the management of hepatocellular carcinoma: A review of literature. Cancer 2009; 115: 4895-4906.
28. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998; 279: 563-566. (Pubitemid 28067285)
29. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 1393-1396. (Pubitemid 28209997)
30. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999; 91: 620-625. (Pubitemid 29194048)
31. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X: Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis. J Natl Cancer Inst 1999; 91: 151-156. (Pubitemid 29042692)